ERBB2 and breast carcinoma: Endocrine therapy combined with double blocking HER2 therapy significantly improved PFS, which may be considered for the selection of HER2+/HE+ breast cancer patients.273,294 The randomized clinical trials showed its efficacy to be inferior to that of chemotherapy plus anti-HER2 regimens.